P/E ratio for Rubius Therapeutics (RUBY)
P/E ratio as of May 2024 (TTM): -0.0092
According to Rubius Therapeutics 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.00923445. At the end of 2021 the company had a P/E ratio of -4.34.
P/E ratio history for Rubius Therapeutics from 2018 to 2022
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2021 | -4.34 | 18.96% |
| 2020 | -3.65 | -20.49% |
| 2019 | -4.59 | -18.06% |
| 2018 | -5.60 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 ORIC Pharmaceuticals
ORIC | -4.28 | 46,246.24% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.